Allurion Technologies Reports Q2 Results and Strategic Pivot

Allurion Technologies ( (ALUR) ) has issued an update.

On August 13, 2025, Allurion Technologies announced its second quarter financial results, revealing a strategic pivot towards low-dose GLP-1 combination therapy and U.S. market entry. The company reported a revenue of $3.4 million for the quarter, reflecting a decrease due to distributor transitions and reduced sales in certain markets. Despite this, Allurion is optimistic about long-term growth through new strategic partnerships and a focus on next-generation R&D, aiming to establish a new standard of care in obesity management.

The most recent analyst rating on (ALUR) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.

Spark’s Take on ALUR Stock

According to Spark, TipRanks’ AI Analyst, ALUR is a Neutral.

The overall score is heavily influenced by Allurion’s challenging financial position, including high leverage and negative cash flows. While the earnings call shows some operational improvements, these are not yet sufficient to offset financial weaknesses. Technical analysis and valuation scores reflect ongoing uncertainties about future profitability.

To see Spark’s full report on ALUR stock, click here.

More about Allurion Technologies

Allurion Technologies, Inc. is a pioneer in metabolically healthy weight loss, offering a weight-loss platform that includes the Allurion Gastric Balloon, a swallowable, procedureless gastric balloon for weight loss, and the Allurion Virtual Care Suite. The company focuses on innovative weight-loss solutions that maintain muscle mass and is preparing for a potential U.S. market entry.

Average Trading Volume: 297,898

Technical Sentiment Signal: Strong Sell

Current Market Cap: $19.24M

See more data about ALUR stock on TipRanks’ Stock Analysis page.